Despite our increased understanding of DHL/THL biology and advances made in the therapeutic management of these therapy-evasive HGBL with MYC and BCL2 and/or BCL6 rearrangements, the nosological characterization of DHL/THL remains incomplete, necessitating transnational or multicenter large cohort studies to unravel relevant disease-specific genetic and clinicopathological features, as well as risk factors for appropriate characterization of risk-adapted therapeutic strategies [11,12,13,14,15,16,20]. This evidence concerns the gene TCHH and high grade B-cell lymphoma.